# Mycobacterium bovis Bacillus Calmette-Guérin (BCG)-Related Sternal Osteomyelitis

**Authors:** Belkis Hatice Inceli, Döndü Nilay Penezoglu, Halil Özdemir, Gül Arga, Seda Kaynak Sahap, Ömer Suat Fitoz, Koray Ceyhan, Ayten Kayi Cangir, Zehra Sule Haskologlu, Ergin Çiftçi

PMC · DOI: 10.7759/cureus.78054 · Cureus · 2025-01-27

## TL;DR

A healthy child developed rare BCG vaccine-related sternal osteomyelitis, diagnosed through imaging and biopsy, and successfully treated with antibiotics.

## Contribution

This case highlights a rare complication of BCG vaccination and its successful management in an immunocompetent child.

## Key findings

- BCG-related granulomatous osteomyelitis was diagnosed via imaging and biopsy in an 11-month-old child.
- Mycobacterium bovis was isolated from the biopsy material, confirming the diagnosis.
- Antibiotic treatment led to a 90% reduction in lesion size within one month.

## Abstract

Although the Bacillus Calmette-Guérin (BCG) vaccine causes some complications such as lymphadenitis, cellulitis, and localized musculoskeletal diseases after administration, post-vaccine osteomyelitis is one of the rare complications in healthy children. Diagnosis is often delayed due to atypical presentation. An 11-month-old boy with a normal immune system, who was previously known to be completely healthy and had been vaccinated with BCG, was referred to our center due to a newly noticed firm swelling on the anterior chest wall. There was no evidence of previous tuberculosis infection or contact with a tuberculosis patient. In thorax computed tomography (CT) and magnetic resonance imaging (MRI), there was an irregular soft tissue appearance with heterogeneous contrast, causing lytic changes in the sternum. Histopathological examination of the fine needle aspiration biopsy performed for diagnostic purposes was found to be compatible with post-vaccination BCG-related granulomatous osteomyelitis. Mycobacterium bovis was isolated in the culture sent from the biopsy material. The patient was started on isoniazid, rifampicin, ethambutol, and ciprofloxacin treatments. No complications developed during the treatment, and in the follow-up imaging one month later, a significant shrinkage of the lesion (90%) was detected compared to the previous examination.

## Linked entities

- **Chemicals:** isoniazid (PubChem CID 3767), rifampicin (PubChem CID 135398735), ethambutol (PubChem CID 14052), ciprofloxacin (PubChem CID 2764)
- **Diseases:** osteomyelitis (MONDO:0005246), tuberculosis (MONDO:0018076)

## Full-text entities

- **Diseases:** cellulitis (MESH:D002481), swelling (MESH:D004487), lymphadenitis (MESH:D008199), granulomatous (MESH:D013968), musculoskeletal diseases (MESH:D009140), tuberculosis (MESH:D014376), Sternal Osteomyelitis (MESH:C537489), osteomyelitis (MESH:D010019)
- **Chemicals:** rifampicin (MESH:D012293), isoniazid (MESH:D007538), ciprofloxacin (MESH:D002939), ethambutol (MESH:D004977)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mycobacterium tuberculosis variant bovis (biotype) [taxon 1765]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11863292/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11863292/full.md

## References

20 references — full list in the complete paper: https://tomesphere.com/paper/PMC11863292/full.md

---
Source: https://tomesphere.com/paper/PMC11863292